RecruitingPhase 2

Effect of CoQ10 on the Outcome of MAFLD Patients

Egypt60 participantsStarted 2023-10-31

Plain-language summary

So far there has been no universal treatment for MAFLD since it has a complex etiology that involves ethnic, genetic, metabolic and environmental factors. However, therapeutic life changes including: diet, weight loss, and physical activity remain the cornerstone of treatment and is recommended by both American and European associations. Inflammatory biomarkers, such as tumor necrosis factor-alpha, and adipokines play key roles in the pathogenesis of MAFLD, hence, the anti-inflammatory and antioxidant effects of coenzyme Q10 especially at high doses that have not been tested are hypothesized to have a beneficial role in improving the systemic inflammation and biochemical variables. This study is conducted to test this hypothesis

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Waist circumference (WC) ≥ 102/88 cm for men and women respectively.
✓. HDL cholesterol \<40 mg/dl in men and \<50 mg/dl in women or on specific drug therapy.
✓. Plasma Triglycerides ≥ 150 mg/dl or on specific drug therapy.
✓. Blood pressure ≥130 and/or ≥ 85 or on specific anti-hypertensive therapy.
✓. Fasting blood glucose ≥ 100 mg/dl or on specific anti hyperglycemic therapy

What they're measuring

Change in liver steatosis degree

Timeframe: Baseline and at 12 weeks

Trial details

NCT IDNCT05984745

SponsorAin Shams University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-07

Contact for this trial

Mariam Seif

+201112720114 mariam.talaat@pharma.asu.edu.eg

View on ClinicalTrials.gov More Fatty Liver trials